Contemporary view on liver impairment in heart failure

Česká verzia

Authors: K. Vyskočilová; L. Špinarová
Authors place of work: I. interní kardio-angiologická klinika Lékařské fakulty MU a FN u sv. Anny v Brně – ICRC Brno, přednostka prof. MUDr. Lenka Špinarová, Ph. D., FESC
Published in the journal: Vnitř Lék 2013; 59(12): 1065-1072
Category: Přehledný referát

Summary

Cardiac failure has a negative impact on the function of all parenchymatous organs, based both on the low organ perfusion in the left-sided forward failure and on the venous congestion in the right-sided backward failure. Current studies dealing with the cardiac hepatopathy focus not only on the liver enzyme changes, but also analyse its clinical and prognostic relevance. The aim of the article is to provide the comprehensive and contemporary view on liver dysfunction in heart failure patients.

Key words:
heart failure – liver function tests – bilirubin – congestive hepatopathy – ischemic hepatitis

Zdroje

1. Mebazaa A. Congestion and cardiorenal syndromes. Contrib Nephrol 2010; 165: 140–144.

2. Mentz RJ, O’Conor CM. Cardiorenal syndrome clinical trial end points. Heart Fail Clin 2011; 7: 519–528.

3. Poelzl G, Ess M, Mussner-Seeber C et al. Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance. Eur J Clin Invest 2012; 42: 153–163.

4. Myers RP, Cerini R, Sayegh R et al. Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology 2003; 37: 393–400.

5. Jolliffe N. Liver function in congestive heart failure. J Clin Invest 1930; 8: 419–433.

6. Felder L, Mund A, Parker JG. Liver function tests in chronic congestive heart failure. Circulation 1950; 2: 286–297.

7. Kubo SH, Walter BA, John DH et al. Liver function abnormalities in chronic heart failure. Influence of systemic hemodynamics. Arch Intern Med 1987; 147: 1227–1230.

8. White TJ, Wallace RB, Gnassi AM. Hepatic abnormalities in congestive heart failure: needle biopsy studies. Circulation 1951; 3: 59–64.

9. Killip T, Payne MA. High serum transaminase activity in heart disease. Circulatory failure and hepatic necrosis. Circulation 1960; 21: 646–660.

10. Allen LA, Felker GM, Pocock S et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Eur J Heart Fail 2009; 11: 170–177.

11. Batin P, Wickens M, McEntegart D et al. The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 1995; 16: 1613–1618.

12. Van Deursen VM, Damman K, Hillege HL et al. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail 2010; 16: 84–90.

13. Shinagawa H, Inomata T, Koitabashi T et al. Prognostic significance of increased serum bilirubin levels coincident with cardiac decompensation in chronic heart failure. Circ J 2008; 72: 364–369.

14. Lau GT, Tan HC, Kritharides L. Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. Am J Cardiol 2002; 90: 1405–1409.

15. Chang CY, Schiano TD. Review article: drug hepatotoxicity. Aliment Pharmacol Ther 2007; 25: 1135–1151.

16. Henrion J, Schapira M, Luwaert R et al. Hypoxic hepatitis. Clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 2003; 82: 392–406.

17. Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: Clinical presentation and pathogenesis. Am J Med 2000; 15: 109–113.

18. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495–500.

19. Maleki M, Vakilian F, Amin A. Liver diseases in heart failure. Heart Asia 2011; 20: 143–149.

20. Herzer K, Kneiseler G, Bechmann LP et al. Onset of heart failure determines the hepatic cell death pattern. Ann Hepatol 2011; 2: 174–179.

21. Málek F, Hendrichová M, Krátká K et al. Correlation of functional liver mass with left ventricular ejection fraction and left atrial diameter in patients with congestive heart failure. Int J Cardiol 2008; 127: 271–273.

22. Calderon RM, Cubeddu LX, Goldberg RB et al. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc 2010; 85: 349–356.

23. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005–2023.

24. Fracanzani AL, Burdick L, Raselli S et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008; 121: 72–78.

25. Kim D, Kim WR, Kim HJ et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357–1365.

26. Van Lingen R, Warshow U, Dalton HR et al. Jaundice as a presentation of heart failure. J R Soc Med 2005; 98: 357–359.

27. Naschitz JE, Slobodin G, Lewis RJ et al. Heart diseases affecting the liver and liver diseases affecting the heart. Am Heart J 2000; 140: 111–120.

28. Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology 1995; 21: 1232–1237.

29. Bynum TE, Boitnott JK, Maddrey WC. Ischemic hepatitis. Dig Dis Sci 1979; 24: 129–135.

30. Henrion J, Descamps O, Luwaert R et al. Hypoxic hepatitis in patients with cardiac failure: incidence in a coronary care unit and measurement of hepatic blood flow. J Hepatol 1994; 21: 696–703.

31. Raurich JM, Llompart-Pou JA, Ferreruela M et al. Hypoxic hepatitis in critically ill patients: incidence, etiology and risk factors for mortality. J Anesth 2011; 25: 50–56.

32. Brodanová M. Choroby jater. In: Klener P et al (eds). Vnitřní lékařství. Praha: Galén-Karolinum 2006: 631–632.

33. Hopper I, Kemp VV, Porapakkham P et al. Impact of heart failure and changes to volume on liver stiffness: non-invasive assessment using transient elastography. Eur J Heart Fail 2012; 14: 621–627.

34. Colli A, Pozzoni P, Berzuini A et al. Decompensated chronic heart failure: Increased liver stiffness measured by means of transient elastography. Radiology 2010; 257: 872–878.

35. Ebinuma H, Saito H, Komuta M et al. Evaluation of liver fibrosis by transient elastography using acoustic radiation force impulse: comparison with Fibroscan®. J Gastroenterol 2011; 46: 1238–1248.

36. Sporea I, Sirli R, Bota S et al. Comparative study concerning the value of acoustic radiation force impulse elastography (ARFI) in comparison with transient elastography (TE) for the assessment of liver fibrosis in patients with chronic hepatitis B and C. Ultrasound Med Biol 2012; 38: 1310–1316.

37. Petrtýl J, Brůhal R, Urbánek P et al. Katetrizace jaterních žil – vybrané aspekty hodnocení. Vnitř Lék 2013; 59: 587–590.

38. Ambrosy AP, Vaduganathan M, Huffman MD et al. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail 2012; 14: 302–311.

39. Ess M, Mussner-Seeber C, Mariacher S et al. Gamma-glutamyltransferase rather than total bilirubin predicts outcome in chronic heart failure. J Card Fail 2011; 17: 577–584.

40. Poelzl G, Eberl C, Achrainer H et al. Prevalence and prognostic significance of elevated gamma-glutamyltransferase in chronic heart failure. Circ Heart Fail 2009; 2: 294–302.

41. Dichtl W, Vogel W, Dunst KM et al. Cardiac hepatopathy before and after heart transplantation. Transpl Int 2005; 18: 697–702.